Publicly-traded company Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) had a closing price of $0.51 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $2.00, this means that the stock is underpriced by 74.5%. In the past 52 weeks the company’s stock price has moved within the range of $0.45 to $4.25.
This particular stock’s 5-day moving average is 0.52, its 20-day moving average is 0.53 and its 100-day moving average is 0.67. Aerpio Pharmaceuticals Inc. (ARPO) currently has 39.07M shares outstanding, which means that its market capitalization is $19.87M.
The Details: Aerpio Pharmaceuticals Inc. (ARPO) Financial Health
Return on Assets is a number, expressed as a percentage that tells us how well a publicly-traded company is using its current assets to generate revenue. The higher the percentage, the better a company is using its assets to turn a profit. At the moment, Aerpio Pharmaceuticals Inc. Return on Assets is -51.00%.
What Does Wall Street Say about Company?
When choosing stocks, many investors search for what Wall Street professionals think about the company first – like what the average rating is. At the moment, the average analyst rating for ARPO is Overweight. Out of 2 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 1 rated it hold, and 1 rated it a Buy.
Three months ago, on the other hand, the average analyst rating for Aerpio Pharmaceuticals Inc. (ARPO) was a Overweight – from a survey of 2 analysts. Of the analysts who provided ratings, 1 rated the company a Hold, 0 rated it a Sell, 0 rated it an overweight, 0 rated it an underweight, and 1 rated it a Buy.
Understanding Profitability at Aerpio Pharmaceuticals Inc. (ARPO)
Taking a look at a public company’s Earnings per Share (EPS) is a good way of evaluating its profitability. In the most recent financial results released by Aerpio Pharmaceuticals Inc., for the quarter ending on 12/2019, the company posted EPS of -0.12. The average estimate of Wall Street analysts had projected -0.12.
Wall Street analysts, on average, are forecasting the company’s EPS to be -0.12, compared to -0.21 reported in the same quarter last year.